Inosine in Early Parkinson's Disease (SURE-PD3)

Phase 3 Completed

Early Parkinson's Disease

NCT ID NCT02642393 ↗

Phase Phase 3

Status Completed

Sponsor NINDS / MJFF

Enrolment n = 298

Last updated 2026-04-30

Registered 2026-04-30

Target intervention

Inosine to elevate serum urate

Primary endpoint

MDS-UPDRS Parts I-III change at 24 months

Summary

Failed primary endpoint despite Mendelian-randomization support for urate→PD; classic example of MR-justified target failing in trial.

Protocol timeline

Phase I

Phase II

Phase III

Phase IV

Current status Completed

Enrolled n = 298

View on ClinicalTrials.gov ↗

POST /api/scidex/rpc { "verb": "scidex.get", "args": { "ref": { "type": "clinical_trial", "id": "ct-8a19f66f271d" }, "include_content": true, "include_provenance": true, "actions": [ "signal_vote", "add_comment" ] } }